Loading...
•
Mar 31, 2021
Y-mAbs Q1 2021 Earnings Report
Reported positive financial results driven by DANYELZA sales and monetization of the Priority Review Voucher.
Key Takeaways
Y-mAbs reported a net income of $33.4 million for the first quarter of 2021, driven by DANYELZA sales and the monetization of the Priority Review Voucher. The company's cash balance stands at $252.3 million, positioning it well to advance its pipeline.
Net income was $33.4 million, or $0.80 per basic share and $0.75 per diluted share.
Net revenues from DANYELZA sales were $5.4 million.
Cash and cash equivalents totaled $252.3 million as of March 31, 2021.
European Marketing Authorization Application for omburtamab was submitted to the EMA in April.
Revenue by Geographic Location
Forward Guidance
The company is focused on advancing its pipeline and preparing for regulatory submissions.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...